Patient recruitment is the administrative process of identifying, approaching, screening, and enrolling participants who meet a clinical trial’s eligibility criteria. It is one of the most operationally demanding parts of running a trial: a protocol can be scientifically sound and fully funded and still stall for months if the site cannot find and enroll enough eligible participants. For a research administrator, recruitment is not a single task but a coordinated set of activities — selecting channels, getting materials through IRB review, screening prospective participants against eligibility criteria, obtaining informed consent, and tracking outcomes — all of which have direct downstream effects on the trial’s timeline and budget.
This guide covers the main recruitment channels and the compliance requirement that applies to nearly all of them, how screening connects to the informed consent process, the administrative problems that most commonly slow enrollment and how they are tracked, and how recruitment performance feeds into trial timeline and budget planning.
What Counts as Patient Recruitment in a Clinical Trial
Recruitment covers everything from the first point of contact with a prospective participant through the decision to formally screen them against the protocol’s eligibility criteria. It is distinct from, but feeds directly into, enrollment — the point at which a screened, consented participant is formally entered into the study, typically via randomization or assignment to a study arm. Recruitment activity is usually measured and reported separately from enrollment because the two have different failure points: a recruitment shortfall means too few people are being reached or expressing interest, while a screening/eligibility shortfall means enough people are being reached but too few of them qualify.
The site or sponsor typically documents a recruitment plan as part of the overall protocol and regulatory submission — describing the intended channels, the target population, projected accrual rate, and the materials that will be used. IRBs and, for NIH-funded studies, the funding institute review this plan alongside the science, because how participants are recruited has direct human-subjects-protection implications (see the advertising requirement below).
Recruitment Methods and Channels
Most trials use a combination of the following channels rather than relying on just one:
- Physician/clinician referral. A treating physician, often at the enrolling site itself or at a referring practice, identifies a patient who may be eligible and discusses the trial with them or refers them to the study team. This remains one of the highest-yield and highest-trust channels, but it depends on referring clinicians being aware the trial exists and having an efficient referral pathway — a real operational bottleneck at sites that rely on informal, word-of-mouth referral rather than a structured process.
- Patient registries. Disease-specific or condition-specific registries (maintained by health systems, patient advocacy organizations, or research networks) allow investigators to identify and contact individuals who have already indicated interest in research participation or who carry a relevant diagnosis. Registries can substantially shorten the time to first contact compared to open recruitment, but using one requires its own IRB-reviewed process for how contact is initiated and what information the registry may disclose before consent.
- Community outreach. Presentations to patient advocacy groups, community health fairs, partnerships with community organizations, and outreach through primary care networks. This channel is frequently the mechanism sites use to reach populations that are underrepresented in a given trial’s current pool — directly relevant to the inclusion requirements discussed below.
- Digital and social media recruitment. Paid search, social media advertising, recruitment-specific study-matching platforms, and sponsor or institutional websites. This channel has grown substantially because it can target narrow eligibility profiles (age range, condition, geography) at a scale that referral and outreach cannot match, but it is also the channel most likely to be reviewed closely by an IRB, since digital ad copy, images, and targeting criteria are all considered part of the advertisement.
Advertising Materials Require IRB Approval Before Use
This is a compliance point that is easy to underestimate: FDA and the Office for Human Research Protections (OHRP) treat direct advertising for research subjects as the start of the informed consent and subject-selection process, not as separate marketing activity outside the IRB’s purview. FDA’s guidance on recruiting study subjects states that direct advertising — newspaper, radio, TV, bulletin boards, posters, flyers, and digital/social media ad copy, images, and video intended for prospective subjects — should be reviewed and approved by the IRB as part of the initial review package, and any revisions to that material also require IRB approval before use.
When reviewing advertising, IRBs evaluate the mode of communication and the information contained in it to confirm the recruitment approach is not coercive and does not state or imply a certainty of favorable outcome or benefits beyond what the informed consent document and protocol actually describe, and that risk and potential-benefit information is presented in a fair, balanced way. In practice this means a site cannot simply hand a marketing or communications team a study summary and let them produce ad copy independently — every substantive claim in the material has to trace back to what the protocol and consent form actually say.
There is a narrow, commonly used exemption: basic study listings on the internet do not require separate IRB approval when the format limits the information to the title, purpose of the study, protocol summary, basic eligibility criteria, study site location, and how to contact the site for more information — the kind of listing format ClinicalTrials.gov itself uses. Anything beyond that basic-information format (persuasive language, testimonials, benefit claims, targeted ad creative) falls back under the standard IRB review requirement.
See CASRAI’s guide to the IRB/REC approval process for how this fits into the broader review pathway, and the IRB (Institutional Review Board) dictionary entry for the underlying definition.
Screening and the Informed Consent Process
Once a prospective participant has been reached through one of the channels above, the site moves into screening: applying the protocol’s inclusion and exclusion criteria to determine whether the person actually qualifies for the study. Screening typically happens in stages:
- Pre-screening. An initial, often lighter-touch check — sometimes against existing medical records, a brief phone or online questionnaire, or registry data — to filter out people who clearly do not meet basic criteria before committing to a full screening visit. Pre-screening against a person’s own existing medical record, done by their own treating clinician for the purpose of identifying trial candidates, is generally treated differently under the Common Rule and HIPAA than pre-screening that involves accessing another provider’s records or a third party’s data.
- Formal eligibility screening. A dedicated visit or set of assessments (lab work, imaging, a physical exam, a diagnostic confirmation) that generates the actual data used to determine protocol eligibility. This is also where informed consent has to occur — before any study-specific procedure that would not otherwise happen as part of the person’s routine care.
Consent has to precede screening procedures that go beyond standard-of-care activity, which is why recruitment, screening, and informed consent are administratively inseparable in practice even though they are conceptually distinct steps. CASRAI’s guide to informed consent in research covers what the consent process itself requires in detail — voluntary participation, disclosure, comprehension, capacity, and an ongoing right to withdraw — and is the natural next read once a participant reaches this stage. The informed consent dictionary entry gives the operational definition CASRAI uses across its content.
Common Enrollment Challenges and Administrative Solutions
Screen Failures and Screen-Failure Tracking
A screen failure is a prospective participant who was formally screened but did not meet the protocol’s eligibility criteria (or who withdrew before enrollment for a reason unrelated to eligibility). Screen failures are expected and unavoidable to some degree — not every prospective participant who is worth screening will qualify — but a high or rising screen-failure rate is one of the clearest early-warning signals that either the eligibility criteria are too narrow for the available population, the pre-screening step isn’t filtering effectively before the more resource-intensive formal screening visit, or the wrong population is being targeted through the channels in use.
Because screening visits consume real site resources (staff time, lab and imaging capacity, sometimes participant reimbursement for the screening visit itself), sites and sponsors track the screen-failure rate as a standard recruitment KPI, usually reported through the site’s clinical trial management system (CTMS) or a dedicated recruitment-tracking module. See CASRAI’s guide to the Clinical Trial Management System (CTMS) for how this tracking function fits into the broader trial-management toolset. A pattern of high screen failures against a specific inclusion/exclusion criterion is also useful protocol-amendment evidence — sponsors sometimes loosen an overly restrictive criterion mid-trial once real screening data show it is excluding an unexpectedly large share of an otherwise-eligible population.
Diversity and Inclusion Requirements
For NIH-funded clinical research, recruitment planning is also shaped directly by federal policy, not just by scientific and operational considerations. Two NIH inclusion policies are the ones a research administrator most commonly has to plan recruitment against:
- The NIH Policy and Guidelines on the Inclusion of Women and Members of Racial and/or Ethnic Minority Groups in Clinical Research, grounded in section 492B of the Public Health Service Act (42 U.S.C. § 289a-2), requires that women and members of racial and ethnic minority groups be included in NIH-funded clinical research in a manner appropriate to the scientific question under study, unless a clear and compelling scientific or ethical rationale justifies their exclusion. Applications must describe the planned study population by sex and race/ethnicity, provide a scientific rationale for that composition, and — for Phase III clinical trials specifically — plan for a valid analysis of whether outcomes differ by sex and by race/ethnicity. Sex, race, and ethnicity data must be collected and reported in progress reports. The policy’s guidance was most recently revised via NIH Notice NOT-OD-25-131 (posted July 2025), which updated terminology to align with current federal race/ethnicity and sex data-collection standards.
- The NIH Policy on the Inclusion of Individuals Across the Lifespan requires that individuals of all ages — including children and older adults — be included in NIH-funded human subjects research unless there is a scientific or ethical reason not to, and applies to applications submitted for due dates on or after January 25, 2019. Applications must justify any age-based exclusion, and grant budgets are expected to account for the recruitment and retention costs associated with reaching participants across the full relevant age range.
Practically, both policies mean the recruitment plan itself — not just the trial design — has to be built to reach a representative population, and that recruitment outreach (community partnerships, translated materials, registry access in underrepresented communities) is often the mechanism by which a site actually meets these requirements rather than an afterthought layered on top of a channel strategy built around convenience.
Site-Level Under-Enrollment
Recruitment shortfalls are not evenly distributed across a multi-site trial — some sites reliably meet or exceed their enrollment target while others under-enroll or, in some cases, fail to enroll a single eligible participant despite being activated for the study. This is a well-documented pattern in industry benchmarking research (most frequently associated with the Tufts Center for the Study of Drug Development’s periodic studies of accrual performance), and it is one reason sponsors build recruitment contingency into a multi-site design from the outset — over-activating sites relative to the minimum needed, building in a mid-study recruitment review checkpoint, and being prepared to reallocate enrollment targets or add sites if early accrual data show a site is unlikely to meet its target.
How Recruitment Connects to Trial Timeline and Budget Planning
Recruitment and enrollment delays are consistently identified, across clinical-operations benchmarking research, as one of the leading drivers of clinical trial timeline extensions — more so than delays in trial startup, data management, or closeout activities in many reported analyses. That makes recruitment planning a direct input into two things a research administrator is responsible for, not just a clinical-operations concern:
- Timeline planning. Enrollment duration is typically the least predictable phase of the trial lifecycle covered in CASRAI’s guide to clinical trial phases, because it depends on real-world accrual rates rather than a fixed protocol-driven duration the way, say, a fixed follow-up period does. Realistic timeline planning accounts for a recruitment ramp-up period, a steady-state accrual rate estimated from comparable trials or the site’s own historical performance, and contingency time for a slower-than-projected start. When enrollment does run long, the administrative mechanism for extending the award period without adding new funds is typically a no-cost extension (NCE) — recruitment delay is one of the most common reasons an NCE is requested.
- Budget planning. Recruitment has real, budgetable costs: advertising placement and production, registry access fees, community outreach staff time, and the cost of screening (including screen failures, which consume site resources without producing an enrolled participant). Sponsors and sites typically build a per-participant recruitment cost estimate into the trial budget that explicitly accounts for an assumed screen-failure rate — if 1 in 3 screened candidates is expected to fail screening, the budget for screening visits, labs, and any consent-related activity needs to reflect the total number screened, not just the number ultimately enrolled.
Operationally, recruitment is coordinated day to day by the Clinical Research Coordinator (CRC) at the site level — managing referral intake, scheduling screening visits, and tracking screen-failure and enrollment data — while the Clinical Research Associate (CRA) monitors enrollment progress against the protocol and plan on the sponsor or CRO side, and flags sites that are falling behind target. Research administrators overseeing multiple trials, or credentialed via a program like the Certified Research Administrator (CRA) credential, use recruitment and screen-failure metrics as a standard part of trial-portfolio status reporting, alongside budget burn and milestone tracking.
Frequently Asked Questions
Do all recruitment advertisements need IRB approval?
Direct advertising intended for prospective participants — print, broadcast, posters, flyers, and digital/social media ad copy and creative — generally needs IRB review and approval before use, including any revisions. The narrow exception is a basic internet study listing limited to information such as the title, purpose, protocol summary, basic eligibility criteria, and site location/contact information, in the format used by resources like ClinicalTrials.gov.
What is the difference between recruitment and enrollment in a clinical trial?
Recruitment covers identifying and reaching prospective participants and screening them against eligibility criteria. Enrollment is the formal step of entering a screened, consented participant into the study, typically through randomization or assignment to a study arm. A person can be recruited and screened without ever being enrolled — that outcome is a screen failure.
What is a screen failure?
A screen failure is a prospective participant who underwent formal eligibility screening but did not meet the protocol’s inclusion/exclusion criteria, or who withdrew before enrollment for reasons unrelated to eligibility. Screen-failure rate is tracked as a recruitment performance metric because it directly affects both timeline and budget.
Do NIH-funded trials have specific diversity requirements for recruitment?
Yes. NIH-funded clinical research must plan for the inclusion of women and members of racial and ethnic minority groups, per the Public Health Service Act (42 U.S.C. § 289a-2) and its implementing NIH policy, and must plan for age-appropriate inclusion across the lifespan under a separate NIH policy applicable to applications submitted on or after January 25, 2019. Both requirements shape the recruitment plan itself, not just the study design.
How does recruitment affect a clinical trial’s budget?
Recruitment carries direct costs — advertising, registry access, outreach staff time — and indirect costs through screening, since every screened candidate (including those who ultimately screen-fail) consumes site resources. Trial budgets typically build in a per-participant recruitment and screening cost that accounts for an assumed screen-failure rate, not just the target enrollment number.
